Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept’s NASH Drug Delayed By April Advisory Committee

Dec 17 2019

• By Joseph Haas

liver

Related Content

Will A US FDA Advisory Committee Be In Intercept's Future?

Oct 01 2019

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

Dec 14 2019

Indian Policy Shifts Could Force Firms To Abandon 'Second Brand' Strategies

Aug 22 2017

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Nov 11 2019

Related Companies

Intercept Pharmaceuticals, Inc.

Amarin Corp plc

Additional Topics

United States Advisory Committees Drug Review Regulation Liver & Hepatic BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window